Merck First US Pharma Giant To Abandon COVID Vaccine Efforts


New Jersey-based Merck, one of the world’s largest pharmaceutical companies, has just abandoned its two experimental COVID vaccine projects after early data showed they generated little, if any, immune response in patients.

Merck’s shares took a hit on the news, tumbling nearly 2%, as the company – which has a long history of developing vaccines (though typically on a longer timeline) – adopted a different strategy from rivals like Pfizer, Moderna and J&J. Merck used a more traditional approach focusing on weakened viruses. One approach, called V590, used technology from Merck’s Ebola inoculation efforts, while the other, known as V591, was based on a measles vaccine used in Europe.

Merck has lagged peers like Pfizer, JNJ and GSK for pretty much the entire time, while its lab results were “disappointing, and “a bit of a surprise,” said Nick Kartsonis, Merck’s senior vice president of clinical research for infectious diseases and vaccines at Merck Research Laboratories. – READ MORE

Listen to the insightful Thomas Paine Podcast Below --

No Comments Yet

Leave a Reply

2021 © True Pundit. All rights reserved.